Codexis (CDXS) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Codexis (CDXS) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Codexis |
213.30 Mn |
148.16 Mn |
13.18 Mn |
57.93% |
| Date | Value |
|---|
| Mar 31, 2026 |
57.93% |
| Dec 31, 2025 |
192.53% |
| Sep 30, 2025 |
4.97% |
| Jun 30, 2025 |
41.67% |
| Mar 31, 2025 |
-79.82% |
| Dec 31, 2024 |
-44.27% |
| Sep 30, 2024 |
40.87% |
| Jun 30, 2024 |
-97.47% |
| Mar 31, 2024 |
49.13% |
| Dec 31, 2023 |
42.94% |
| Sep 30, 2023 |
-249.36% |
| Jun 30, 2023 |
-336.48% |
| Mar 31, 2023 |
-170.67% |
| Dec 31, 2022 |
-23.69% |
| Sep 30, 2022 |
-545.28% |
| Jun 30, 2022 |
38.10% |
| Mar 31, 2022 |
7.85% |
| Dec 31, 2021 |
-159.95% |
| Sep 30, 2021 |
136.82% |
| Jun 30, 2021 |
32.77% |
